Efficacy of Dalfyra (extended release Fampridine) in fatigue in multiple sclerosis patients
Phase 3
- Conditions
- Fatigue in patients with multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20210429051129N1
- Lead Sponsor
- Qazvin University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Patients with MS over the age of 18 who have not taken Dalfyra for the past year.
Patients have The Expanded Disability Status Scale (EDSS) below 7
Exclusion Criteria
Patients have a kidney problem or a history of seizures.
Patients who are allergic to this drug.
Patients who have had an acute attack in the last 3 months.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fatigue score based on modified fatigue impact scale (MFIS) questionnaire. Timepoint: Both groups complete the Fatigue score based on modified fatigue impact scale (MFIS) questionnaire at the beginning of the study and three months later. Method of measurement: Based on the Fatigue score based on modified fatigue impact scale (MFIS) questionnaire.
- Secondary Outcome Measures
Name Time Method